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See Editorial, pages 1079–1080Background & Aims: Hepatic venous pressure gradient (HVPG)
measurement is currently the only validated technique to accu-
Lay summary: In patients with cirrhosis, the development and
progression of portal hypertension is related to worse outcomes.rately evaluate changes in portal pressure. In this study, we eval-
uate the use of non-contrast quantitative magnetic resonance
imaging (MRI) as a surrogate measure of portal pressure.
Methods: Thirty patients undergoing HVPG measurement were
prospectively recruited. MR parameters of longitudinal relaxation
time (T1), perfusion of the liver and spleen (by arterial spin label-
ling), and blood flow in the portal, splanchnic and collateral circu-
lation (by phase contrast MRI) were assessed. We estimated the
liver stiffness measurement (LSM) and enhanced liver fibrosis
(ELF) score. The correlation of all non-invasive parameters with
HVPG was evaluated.
Results: The mean (range) HVPG of the patients was 9.8 (1–22)
mmHg, and 14 patients (48%) had clinically significant portal
hypertension (CSPH, HVPGP10 mmHg). Liver T1 relaxation time,
splenic artery and superior mesenteric artery velocity correlated
significantly with HVPG. Using multiple linear regression, liver T1
and splenic artery velocity remained as the two parameters in the
multivariate model significantly associated with HVPG (R = 0.90,
p <0.001). This correlation was maintained in patients with CSPH
(R = 0.85, p <0.001). A validation cohort (n = 10) showed this lin-
ear model provided a good prediction of HVPG. LSM and ELF score
correlated significantly with HVPG in the whole population but
the correlation was absent in CSPH.
Conclusions:MR parameters related to both hepatic architecture
and splanchnic haemodynamics correlate significantly with
HVPG. This proposed model, confirmed in a validation cohort,
could replace the invasive HVPG measurement.Journal of Hepatology 20
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invasive and not widely used in clinical practice. Here, we have
studied the use of non-invasive MRI in evaluating portal pressure.
The MRI measures of liver architecture and blood flow in the
splenic artery correlated well with portal pressure. Therefore, this
non-invasive method can potentially be used to assess portal
pressure in clinical trials and monitoring treatment in practice.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The majority of complications in patients with cirrhosis result
from the development and progression of portal hypertension
characterised by increased intrahepatic resistance and progres-
sive splanchnic vasodilation. Distortion of hepatic architecture
resulting from fibrogenesis and nodule formation results in ‘static’
hepatic vascular resistance, whilst a ‘dynamic’ component results
from the active contraction of myofibroblasts and increased hep-
atic vascular tone [1]. The rise of portal pressure is perpetuated by
the excessive release of endogenous vasodilators resulting in
splanchnic vasodilation and increased portal blood flow.
Hepatic venous pressure gradient (HVPG) measurement [2] is
the only validated technique to accurately evaluate changes in
portal pressure. An HVPG threshold of 10 mmHg is termed clini-
cally significant portal hypertension (CSPH) as it predicts the risk
of formation of oesophageal varices [3], clinical decompensation
[4] and development of hepatocellular carcinoma [5]. An HVPG
>12 mmHg is associated with the risk of variceal bleeding [6] and
an HVPG >16 mmHg correlates with increased mortality [7,8],
whilst in acute variceal bleeding an HVPGP20 mmHg is an inde-
pendentprognosticmarker [9]. However, HVPGmeasurements are
invasive and available only in specialised hepatology units, pre-
cluding its use in routine clinical practice. Thus, the development
of non-invasive markers of portal pressure is highly desirable.16 vol. 65 j 1131–1139
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Liver stiffness measurement (LSM) as assessed with transient
elastography (TE) has been suggested as an alternative measure-
ment to HVPG. LSM is thought to reflect hepatic fibrosis and the
resulting intrahepatic resistance. A significant correlation of LSM
with HVPG has been demonstrated at an HVPG <10 mmHg, but
no statistical significance at an HVPG >12 mmHg [10]. This has
led to the suggestion that LSM can identify clinically significant
or severe portal hypertension, but is not a good marker of its sub-
sequent progression. This is likely due to extrahepatic factors,
such as splanchnic vasodilation and a hyperdynamic circulation,
that perpetuate the rise in portal pressure but do not affect the
liver tissue stiffness [11]. TE has also been used to measure
spleen stiffness which is able to identify the presence of varices
and a linear model of spleen and liver stiffness predicting HVPG
with a high accuracy [12]. However, there are significant techni-
cal challenges related to spleen size and an upper detection limit
for tissue stiffness that limit the applicability of this technique.
Magnetic resonance elastography (MRE) has the theoretical
advantage over TE of assessing liver and splenic stiffness across
a larger tissue area. In 36 patients with cirrhosis, MRE-
measured loss modulus of the liver and spleen correlated well
with HVPG (R = 0.44, p = 0.02, and R = 0.57, p = 0.002, respec-
tively) [13]. However, the accessibility of this technique due to
hardware availability and cost, and the feasibility of MRE in some
patients, can limit its clinical translation.
The ratio of liver to spleen volume as measured by computed
tomography has also been shown to predict HVPG, however this
measure has the disadvantage of requiring ionising radiation
[14]. Using Doppler ultrasound, changes in hepatic and splanch-
nic flow in portal hypertension have been studied, but results
have been inconsistent [15], limiting wider use of this technique
[16]. To date, all of these imaging modalities have investigated
individual pathophysiological components of portal
hypertension.
Recent advances in magnetic resonance imaging (MRI) have
made it possible to measure multiple parameters associated with
structural [17], blood flow [18] and perfusion [19] changes in the
liver in a single scan session. Further, since MRI is non-invasive,
repeated assessments are feasible and acceptable. The aim of this
current study is to develop quantitative MRI as a surrogate of
portal pressure. The MRI parameters of interest relate to the size,
architecture and perfusion of the liver and spleen, and changes in
portal and splanchnic blood flow. Specifically, we aim to study
the correlation of these MRI variables with HVPG.Materials and methods
Study population
Consecutive patients undergoing HVPG measurement for clinical indications at
Nottingham University Hospitals NHS Trust and Derby Teaching Hospitals NHS
Foundation Trust between April 2013 and June 2016 were prospectively screened
and included in the study, providing a broad range of HVPG values. We excluded
patients with hepatocellular carcinoma, portal or hepatic vein thrombosis, abso-
lute contraindications for MR, abdominal/waist circumference larger than 112 cm
(due to MR scanner bore constraints), age <18 years and pregnancy.
Thirty-four patients were enrolled for the derivation cohort. Four patients
were excluded from the final analysis; three patients did not complete the MR
scanning protocol due to claustrophobia, one patient had liver histology compat-
ible with non-cirrhotic portal hypertension. MRI and LSM with TE were per-
formed on the same day and within 6 weeks of the HVPG measurement.1132 Journal of Hepatology 2016Patients received no therapeutic interventions between the HVPG measurement
and MRI session.
The study protocol was approved by Staffordshire Research Ethics Committee
(Ref 12/WM/0288). Patients gave written informed consent in accordance with
the principles of the Declaration of Helsinki (revision of Edinburgh 2000).
HVPG measurement
HVPG measurements were carried out by interventional radiologists. HVPG was
measured according to established standards [2] following an overnight fast.
Under ultrasonographic guidance, the right internal jugular vein was cannulated
and a 9-French vascular sheath placed by the modified Seldinger technique. A 6-
French compliant balloon-tipped catheter (Berenstein occlusion catheter, Boston
Scientific, UK) was guided into the right hepatic vein for the measurement of
wedged and free hepatic venous pressures as recommended [8]. All measure-
ments were obtained in triplicate and recorded via a pre-calibrated Philips Intel-
liVue MP50 patient monitor (Philips Healthcare, UK). HVPG was calculated from
the difference between wedged hepatic pressure and free hepatic pressure, and
the mean of triplicate measurements computed.
Liver stiffness measurement (LSM)
LSM was performed prior to the MRI scan, following an overnight fast, using
FibroScan (Echosens, Paris, France) by experienced operators [20]. Due to tech-
nical reasons, LSM values were not available on 2 patients, and measurements on
6 patients were unreliable (median LSM >7.1 kPa and interquartile range/median
ratio >0.30).
Enhanced liver fibrosis (ELF) score
Blood samples were obtained prior to the MRI scan session. Serum samples were
analysed for levels of tissue inhibitor of matrix metalloproteinase-1 (TIMP1), hya-
luronic acid (HA) and aminoterminal peptide of procollagen III (P3NP) at an inde-
pendent reference laboratory (iQur Limited, London, UK). The ELF score was
calculated using an established algorithm [21].
MR data acquisition
All patients were scanned following an overnight fast on a 1.5 Tesla scanner
(Achieva, Philips Medical Systems) with body transmit coil and 16-channel SENSE
torso receive coil. All MR measures were acquired in a 1 h scan session.
Liver and spleen volume
Multi-slice balance turbo field echo (bTFE) localiser images were initially
acquired in three orthogonal directions to locate the anatomy of organs and blood
vessels of interest, and to estimate liver and spleen volume.
Longitudinal relaxation time (T1) of liver and spleen
A modified respiratory triggered inversion recovery sequence with spin-echo
echo planar imaging (SE-EPI) readout (3  3  8 mm3 voxel size, 4 mm slice
gap (33%), 96  96 image matrix, SENSE factor 2, echo time 27 ms) and fat sup-
pression [17] was acquired to estimate the tissue longitudinal relaxation time
(T1) in the liver from 13 inversion times (100–1200 ms in 100 ms steps and
1500 ms). Three sagittal SE-EPI slices were acquired through the right lobe of
the liver with minimal temporal slice spacing (65 ms) in approximately 2 min,
dependent on the patients’ respiratory rate.
In addition, T1 maps of the liver and spleen were acquired using a modified
respiratory triggered inversion recovery sequence with a balanced steady state
free precession (bSSFP, also termed bFFE (balanced fast field echo)) readout
(echo/repetition time = 1.75/3.5 ms, flip angle (FA) 60, linear k-space acquisition,
SENSE 2, resolution 3  3  8 mm3). These maps were primarily collected to yield
voxel wise T1 values for the quantification of perfusion measures (see tissue per-
fusion section), but also provided an alternative T1 measure from a bSSFP readout
scheme as used by others for liver T1 mapping [22]. This readout scheme results
in an apparent recovery time (T1⁄), shorter than the actual longitudinal recovery
time T1 due to the influence of T2/T2⁄ [23]. For coverage of the liver and spleen, 5
coronal-oblique bFFE slices were collected at 9 inversion times (100–900 ms in
100 ms steps) with minimal temporal slice spacing (144 ms) in both ascend
and descend slice acquisition order, thus increasing the dynamic range of inver-
sion time values to (100–1500 ms), with data collected in 3 min.vol. 65 j 1131–1139
Table 1. Clinical and laboratory features of the study population.
Variable All patients (n = 30)
Age, years 55 ± 13
Gender M/F 14/16
BMI 27.0 ± 5.2
Aetiology (%)
Alcohol 9 (30%)
NAFLD 13 (43%)
Autoimmune liver disease 5 (17%)
Histological fibrosis staging
No fibrosis 4 (13%)
Pericellular fibrosis 4 (13%)
Bridging fibrosis 4 (13%)
Cirrhosis 18 (60%)
Aspartate transaminase (AST), U/L 59.6 ± 40.0
Alanine transaminase (ALT), U/L 49.4 ± 38.4
Bilirubin, μmol/L 25.2 ± 26.7
Alkaline phosphatase (ALP), U/L 141.0 ± 106.8
Albumin, g/L 37.7 ± 5.9
Prothrombin time, seconds 11.7 ± 2.1
Platelet count, x109/L 155.7 ± 81.3
Serum sodium, mmol/L 137.8 ± 2.7
Serum creatinine, μmol/L 65.8 ± 23.6
Time between HVPG and MRI, days 25 ± 12
Liver stiffness, kPa 17.5 ± 15.5
HVPG, mmHg 9.8 ± 6.1
HVPG >5 mmHg, n (%) 21 (70%)
CSPH, HVPG ≥10 mmHg, n (%) 14 (47%)
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Splanchnic and portal flow measurements
Phase contrast (PC)-MRI was used to quantify the velocity and cross-sectional
area of the portal vein and hepatic artery (hepatic inflow), and the right, middle,
left hepatic veins (hepatic outflow), as well as the splenic artery (SA) and superior
mesenteric artery (SMA) (flow in splanchnic circulation) and azygous vein (collat-
eral flow). Blood flow in each vessel was measured using a vectorcardiogram
(VCG) gated 2D PC-MR on a single slice perpendicular to each targeted vessel
of interest (echo/repetition time = 4.2/7.5 ms, FA 25, field of view
280  146 mm2, reconstructed resolution 1.5  1.5  6 mm3, SENSE 3, 2 aver-
ages). 15 phases were collected for vein measurements and 20 phases for the
arteries across the cardiac cycle, with defined velocity encoding (VENC) for each
vessel (portal/hepatic/azygous veins VENC = 50 cms1, hepatic/splenic arteries
VENC = 100 cms1, and SMA VENC = 140 cms1). If aliasing occurred, the VENC
was increased and the measure repeated. A flow measurement in each vessel
was obtained in triplicate and the mean calculated. Each measurement was
acquired during a 15–20 s breath-hold, dependent on the subjects’ heart rate.
Tissue perfusion
A multiphase flow alternating inversion recovery arterial spin labelling (ASL)
sequence [24] using a bFFE readout (echo/repetition time = 1.75/3.5 ms, FA 45,
linear k-space acquisition, SENSE 2, resolution 3  3  8 mm3) was used to quan-
tify tissue perfusion in the liver and spleen. Data were collected with patients
breathing freely by introducing a respiratory trigger delay of 200 ms prior to
ASL labelling. Labelling was followed by a multiphase Look-Locker sampling
scheme with an initial delay of 100 ms and subsequent readout spacing of
371 ms with 6 readout phases collected. Liver ASL data was acquired for a sagittal
slice through the right lobe of the liver (50 ASL label/control pairs), whilst spleen
data was acquired for a coronal-oblique slice through the spleen (30 ASL label/
control pairs). In addition, equilibrium base magnetisation (M0) images were
acquired for each slice orientation as well as a T1 map (see Longitudinal relax-
ation time (T1) of liver and spleen section) to allow quantification of perfusion.
MR data analysis
The investigators analysing the MR data were blind to the HVPG measurements.
Liver and spleen volume
Analyze software (Mayo Clinic) was used to draw a region of interest around the
liver and spleen within each bTFE image slice. Total liver and spleen organ vol-
ume was calculated from the sum of the volume measures across all slices.
Longitudinal relaxation time (T1) of liver and spleen
Inversion recovery data were fit to S(t) = M0⁄abs (1–2exp(t/T1)) to
generate T1 and M0 maps for the SE-EPI data, and estimate apparent T1 relaxation
time (T1⁄) for the bFFE data. Binary organ masks were formed from the M0 image
by manual segmentation. Histogram analysis was used to assess the distribution
of relaxation time values within the liver and spleen. For the liver and spleen in
each subject, and for each readout, a histogram of voxel values was fit to a Gaus-
sian function and the peak (distribution mode) used to represent the T1 or T1⁄ tis-
sue relaxation time. This method provides an automated method to eliminate
voxels containing blood in vessels [17]. In addition, the full-width-half-
maximum (FWHM) of the Gaussian function was calculated to reflect the degree
of heterogeneity of relaxation time values. All subjects were confirmed to have
liver tissue T2⁄ >22.6 ms [17].
Splanchnic and portal flow measurements
PC-MR data were analysed using Qflow software (Philips Medical System). For
each vessel, a region of interest was drawn manually around the vessel lumen
on each phase contrast image, with contour detection used. The mean signal
intensity within each region of interest reflects flow velocity in the vessel of inter-
est (cm/s) for each cardiac phase, and the mean velocity across the cardiac cycle
was computed. The cross-sectional area of each vessel lumen was multiplied by
the mean velocity, to compute mean blood flow (ml/s) in each vessel. From trip-
licate measures, the mean and coefficient of variation (CoV) in all flow measures
was estimated.
Liver tissue perfusion
Individual perfusion-weighted difference images (control–label) were calculated
for each of the 6 ASL readout phases. These were inspected for motion (excluding
control/label pairs with movement of >1 voxel) and averaged to create a single
perfusion-weighted (DM) map for each phase. Mean values of DM, the baseJournal of Hepatology 2016equilibrium magnetisation M0 and T1 were used in an iterative model [19] to cal-
culate tissue perfusion (ml/100 g/min) and tissue arrival time of the label (ms),
assuming a T1 of blood at 1.5 T of 1.36 s.
Statistical analysis
Statistical analysis was performed using SPSS software version 21(IBM). Quan-
titative variables were expressed as mean ± standard deviation (SD), and qualita-
tive variables as absolute and relative frequencies. Shapiro-Wilk test was used to
test the normality of the data. HVPG was used as a continuous parameter, and
correlations between variables and HVPG were computed using Pearson’s or
Spearman Rho correlation coefficient (R) as guided by the normal distribution
of the data. MR measures that significantly correlated with HVPG in the univari-
ate analyses were included in a multivariate linear regression analysis. In all anal-
yses, p <0.05 was considered statistically significant. Due to the exploratory
nature of this study, no adjustments were made for multiple comparisons.Results
Patient characteristics
All major clinical and biochemical parameters of the initial
patient group are presented in Table 1. Eighteen patients (60%)
had histological evidence of cirrhosis and 4 patients (13%) had
advanced fibrosis. In those with cirrhosis, 14 patients underwent
oesophagogastroduodenoscopy (OGD) and oesophageal varices
were present in five. In the whole population, nine patients
(30%) had no portal hypertension (HVPG 65 mmHg), 21 patients
(70%) had portal hypertension of which 14 patients (47%) had
clinically significant portal hypertension (HVPG >10 mmHg).vol. 65 j 1131–1139 1133
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ELF markers and LSM as predictors of HVPG
The ELF score correlated significantly with HVPG (Pearson
R = 0.758, p <0.001). There was a significant correlation between
each of the individual components of the ELF score with HVPG;
HA (Spearman R = 0.752, p <0.001), P3NP (Spearman R = 0.607,
p = 0.001) and TIMP1 (Pearson R = 0.512, p = 0.006) (Fig. 1). Valid
LSM, as measured by TE, were available in 22 patients. LSM cor-
related significantly with HVPG (Spearman R = 0.791, p <0.001)
(Fig. 2A). However, for both ELF scores and LSM, there was no sig-
nificant correlation in the subgroup of patients with portal hyper-
tension and CSPH at HVPG >10 mmHg.6
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Fig. 1. Correlation between HVPG and serum markers of liver fibrosis. (A)
Enhanced Liver Fibrosis (ELF) score, (B) hyaluronic acid (HA), (C) aminoterminal
peptide of procollagen III (P3NP) and (D) tissue inhibitor of matrix metallopro-
teinase 1 (TIMP-1) concentrations.
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Considering the whole patient group, there was a statistically sig-
nificant positive correlation between HVPG and SE-EPI liver T1
relaxation time (Pearson R = 0.835, p <0.001; Predicted
HVPG = 585 + 15⁄(Liver SE-EPI T1)) (Fig. 2B). This relationship
was maintained in patients with portal hypertension with HVPG
>5 mmHg (Pearson R = 0.683, p = 0.001) as well as CSPH with
HVPG P10 mmHg (Pearson R = 0.651, p = 0.012). The mean
(± SD) number of voxels in the mask for liver T1 measurements
was 3911(± 1463). The FWHM of the liver SE-EPI T1 Gaussian dis-
tribution showed a significant positive correlation with HVPG
(Spearman R = 0.611, p <0.001) (Fig. 2C), reflecting the increased
heterogeneity in liver T1 with increased severity of portal
hypertension.
The apparent liver relaxation time (T1⁄) measured from bFFE
maps was also a predictor of HVPG. As expected, the bFFE readout
T1⁄ relaxation time was highly correlated with the SE-EPI T1 value
(Pearson R = 0.890, p <0.001), but was lower than that of the
true T1 measured using a SE-EPI readout, (Liver SE-EPI T1) =
141 + 0.92⁄(Liver bFFE T1⁄) (median Gaussian distribution values).
A significant positive correlation of the bFFE T1⁄ relaxation time
with HVPG was found (Pearson R = 0.780, p <0.001), which was
significant for HVPG >5 mmHg (Pearson R = 0.524, p = 0.018).
Spleen T1⁄, estimated from the bFFE readout scheme, corre-
lated with HVPG in the whole patient group (Pearson R = 0.40,
p = 0.028) but this relationship was not significant in patients
with portal hypertension and CSPH with HVPG P10 mmHg.
Fig. 3 illustrates example coronal bFFE T1⁄ maps for patients with
increasing HVPG measures.
Splanchnic and portal flow measures in predicting the HVPG
There was no significant relationship between inflow (portal vein,
hepatic artery or total hepatic inflow) and outflow (right, middle
and left or total hepatic veins) of the liver with HVPG (Table 2).
Whilst in the splanchnic circulation, velocity of the blood flow
in the SMA and SA correlated significantly with HVPG (Pearson
R = 0.534, p = 0.002, R = 0.584, p = 0.003 respectively, Fig. 4A-B).
A significant positive correlation of SA velocity with HVPG was
found for HVPG >5 mmHg (Pearson R = 0.555, p = 0.032), no sig-
nificant correlation with SMA velocity was found for HVPG
>5 mmHg or HVPG P10 mmHg. No significant correlations were
found between SMA or SA velocity at HVPG <10 mmHg, highlight-
ing the haemodynamic changes associated with CSPH. In the azy-
gous vein, velocity and flow correlated significantly with HVPG
(Spearman R = 0.515, p = 0.004 and R = 0.656, p <0.001 respec-
tively) (Fig. 4C). In patients with CSPH, no MR flow parameters
correlated significantly with HVPG. The within session CoV for
PC-MR vessel measures are shown in Table 2.
Tissue perfusion and relationship with HVPG
Valid liver perfusion measurements were obtained in 28 patients
and spleen perfusion measurements in 26 patients. Liver tissue
perfusion correlated positively with HVPG (Spearman R = 0.38,
p = 0.046) and tissue arrival time negatively correlated with
HVPG (Spearman R = 0.467, p = 0.021). However, this relation-
ship was not present in patients with portal hypertension and
CSPH. Spleen tissue perfusion was not related to HVPG.vol. 65 j 1131–1139
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Fig. 2. Correlation of HVPG with imaging markers of liver fibrosis. (A) liver stiffness measurement (LSM), (B) liver SE-EPI T1 relaxation time (ms) and (C) the full-width-
half-maximum (FWHM) of liver SE-EPI T1 Gaussian distribution (ms).
JOURNAL OF HEPATOLOGYSpleen and liver volume and their ratio to predict HVPG
Liver volume and spleen volume did not independently correlate
with HVPG. The ratio of liver/spleen volume negatively correlated
significantly with HVPG (Pearson R = 0.40, p = 0.028), but this
relationship was absent in patients with portal hypertension
and CSPH.
Predictive MR model of HVPG
Table 3 shows those MR parameters that correlated with HVPG in
the univariate analysis. The best predictive model for HVPG (that
provides the minimum sum-of-squares between measured and
predicted HVPG) included liver SE-EPI T1 relaxation time and
SA velocity:
HVPG = 28 + 0.04⁄(Liver SE-EPI T1) + 0.27⁄(SA velocity)
(Spearman R = 0.90, p <0.001),
This correlation was maintained in patients with CSPH
(R = 0.85, p <0.001).3
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Fig. 3. Example of T1 relaxation maps. Top row shows example image quality of
the coronal-oblique imaging slices for base equilibrium M0 data acquired from a
patient with HVPG of 3 mmHg. Subsequent rows show example coronal-oblique
bFFE T1⁄ maps showing the liver and spleen, together with HVPG (mmHg) and
mode of the liver T1⁄ value (ms) across a range of HVPG from 3–22 mmHg, with
columns showing each of the five slices collected for the T1⁄ map.
Journal of Hepatology 2016Validation cohort
Additionally, 10 patients were enrolled to the study as a valida-
tion cohort, which included 4 with non-alcoholic fatty liver dis-
ease, 4 with alcoholic liver disease, 1 each with primary biliary
cholangitis and autoimmune hepatitis. Of these, 4 patients had
portal hypertension, of which 2 had CSPH. In this cohort, there
was a statistically significant positive correlation between HVPG
and the SE-EPI T1 relaxation time of the liver (Pearson R = 0.83,
p = 0.003). Fig. 5 illustrates a Bland-Altman plot showing pre-
dicted HVPG using liver SE-EPI T1 alone, and the combined model
of liver SE-EPI T1 and the haemodynamic measure of SA velocity.
The combined model can be seen to yield an improved estimation
of HVPG, particularly in CSPH.Discussion
In liver cirrhosis, the disruption of sinusoidal architecture with
progressive fibrogenesis and intrahepatic vasoconstriction leads
to an increase in intrahepatic resistance resulting in the rise of
portal pressure. This is further accentuated by splanchnic vasodi-
lation and increased portal blood flow. In the present study we
have demonstrated that a combination of non-invasive quantita-
tive MR measures of liver SE-EPI T1 relaxation time and SA veloc-
ity can provide a non-invasive estimation of portal pressure. The
combined model of structural and haemodynamic MR measures
identified in this study provides the best predictor to accurately
reflect the portal pressures through its full range from normal
to CSPH (Fig. 5).
The relationship between the degree of hepatic fibrosis and
portal pressure has been reported from studies comparing histo-
logical changes in liver biopsy with HVPG. For example, quantita-
tive liver biopsy analysis with collagen proportionate area
measurement correlated significantly with HVPG [25]. However,
histological analyses are limited by the inherent sampling vari-
ability associated with liver biopsies [26,27]. We have previously
shown that liver T1 relaxation time is associated with the degree
of fibrosis and inflammation in the liver [17]. This acquisition and
analysis approach has been shown to be highly repeatable in
healthy subjects [17], with a CoV between visits of 1.8%, and a
low inter- and intra-observer variability with intra-classvol. 65 j 1131–1139 1135
Table 2. Correlation coefficient and p value of portal, splanchnic and collateral circulation flow parameters as measured by phase contrast MR with HVPG, and the
intra-session coefficient of variation (CoV) of flow measures.
All patient group CSPH, HVPG ≥10 mmHg CoV, % 
(Mean ± SD)Correlation coefficient, R p value Correlation coefficient, R p value
Portal vein
n = 30
Area 0.141 0.464 0.182 0.533 3.0 ± 2.0
Velocity -0.028 0.882 -0.158 0.589 6.3 ± 4.5
Flow 0.105 0.581 0.114 0.698 6.0 ± 3.5
Fraction of total inflow -0.322 0.102 -0.217 0.477
Hepatic artery
n = 28
Area 0.104 0.605 -0.167 0.585 11.5 ± 6.8
Velocity 0.295 0.128 0.327 0.275 12.5 ± 8.3
Flow 0.240 0.218 0.095 0.759 12.5 ± 7.9
Fraction of total inflow 0.322 0.102 0.217 0.477
Total hepatic inflow 0.166 0.407 0.065 0.834
Right hepatic vein
n = 30
Area -0.138 0.482 0.022 0.943 12.3 ± 11
Velocity 0.114 0.548 -0.02 0.947 11.4 ± 9.4
Flow -0.296 0.112 -0.237 0.415 9.5 ± 7.4
Middle hepatic vein
n = 27
Area -0.270 0.183 0.05 0.872 11.8 ± 8.8
Velocity 0.263 0.185 -0.018 0.955 10.4 ± 9.2
Flow 0.016 0.936 -0.358 0.229 11.2 ± 8.3
Left hepatic vein
n = 22
Area -0.001 0.996 -0.067 0.854 12.7 ± 9.4
Velocity 0.060 0.789 0.186 0.607 15.1 ± 11.8
Flow 0.158 0.483 0.232 0.520 11.3 ± 11.4
Total hepatic outflow -0.311 0.131 -0.356 0.233
Superior mesenteric 
artery
n = 30
Area -0.402* 0.031 -0.156 0.595 5.8 ± 4.6
Velocity 0.534** 0.002 -0.253 0.384 4.8 ± 3.4
Flow 0.265 0.156 -0.250 0.389 6.2 ± 4.4
Splenic artery
n = 24
Area -0.107 0.636 -0.201 0.531 9.6 ± 6.0
Velocity 0.584** 0.003 0.572 0.052 8.8 ± 5.6
Flow 0.244 0.250 0.172 0.594 11.1 ± 6.6
Azygous vein
n = 30
Area 0.341 0.065 0.484 0.079 7.9 ± 7.8
Velocity 0.515** 0.004 -0.290 0.314 10 ± 7.4
Flow 0.656** <0.001 0.273 0.345 10.6 ± 7.5
Research Articlecorrelation coefficients of more than 0.99. Here, SE-EPI T1 data
were acquired with fat suppression, removing the effect of fat
on the calculated liver T1 value, which results from the water
liver tissue compartment. In contrast, T1⁄ data acquired with a
bFFE readout is affected by the hepatic fat content in a manner
dependent on the phase between the fat and water signal (as
determined by field strength and repetition time) [28]. Further
since our T1 measurement method is both respiratory triggered
and multi-slice, it allows a large volume of the liver to be sampled
[mean (± SD) of 3911 (± 1463) voxels covering 281 (± 106) cm3]
in a reasonable imaging time without the need for breath-hold,
making this imaging scheme ideal for patient studies. Previous
studies using a modified look-locker inversion recovery (MOLLI)
T1 mapping method with bFFE readout have shown a correlation
with fibrosis [22]. However, this technique requires a breath-hold
for each slice acquired, and it has been shown that hepatic fat
content can be large enough to cause severe MOLLI T1 alterations
[28]. The distribution of liver T1 values (Gaussian FWHM) was
also shown to increase with the worsening portal hypertension,
reflecting the increasing heterogeneity of T1 values across the
liver volume. This emphasises the sampling variability associated
with liver biopsy and potentially TE, and highlights the need for
architectural changes to be studied across the whole liver. In
the subgroup of patients with portal hypertension and CSPH,
the correlation between liver SE-EPI T1 relaxation time and HVPG
remained significant, demonstrating its applicability in assessing1136 Journal of Hepatology 2016portal pressure in patients with severe portal hypertension. There
was no corresponding correlation between LSM and HVPG over
this higher HVPG range in patients with portal hypertension
and CSPH. Our findings are similar to those of Vizutti and col-
leagues who also report that LSM did not correlate with HVPG
>10 mmHg and it is likely that LSM does not reflect the extrahep-
atic haemodynamic changes in advanced portal hypertension.
The correlation between the ELF score and HVPG has not been
previously reported. However, similar to the LSM, the correlation
was lost in patients with portal hypertension and CSPH. A previ-
ous study has demonstrated the correlation of MRE-measured
liver loss modulus with HVPG (r = 0.44, p = 0.02) [13], a lower
correlation than using T1 alone. It would be of interest to use T1
measures in conjunction with MRE-derived assessment of liver
stiffness to assess the prediction of HVPG.
We show a significant correlation between blood flow velocity
in the splanchnic circulation, in SMA and SA with HVPG, which is
likely to represent the hyperdynamic state in portal hyperten-
sion. Previous Doppler ultrasound studies have reported
increased flow in the SMA and SA in patients with cirrhosis
[29] but no direct comparisons with HVPG have been made. Dop-
pler ultrasound has also been widely used to assess the changes
in portal and splanchnic blood flow in liver disease. However, the
reproducibility of Doppler ultrasound has been questionable with
high intra- and inter-observer variation [16,30]. PC-MR is a
non-invasive flow measurement technique without intravenousvol. 65 j 1131–1139
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Fig. 4. Correlation of HVPG with splanchnic and collateral flow. (A) superior
mesenteric artery (SMA) velocity, (B) splenic artery (SA) velocity and (C) azygous
vein (AZV) flow.
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Fig. 5. Predictive MRI model for HVPG. Bland-Altman plot showing the
difference between measured and predicted HVPG against the measured HVPG
using (A) liver SE-EPI T1 relaxation time alone, and (B) predictive MR model of
liver SE-EPI T1 relaxation time and splenic artery velocity. Data shown for original
(blue diamonds) and validation cohort (red squares), with mean difference (solid
line) and ±1.96 standard deviations (broken line) shown.
Table 3. Correlation coefficient and p value of MR variables included in
univariate analysis.
Variable Univariate Multivariate
p valueCorrelation 
coefficient, R
p value
Liver SE-EPI T1 0.835 <0.001 <0.001
Liver bFFE T1* 0.780 <0.001 <0.001
Spleen bFFE T1* 0.400 0.028
Splenic artery velocity 0.584 0.003 0.002
SMA velocity 0.534 0.002
Azygous vein flow 0.656 <0.001
Liver arrival time -0.572 0.004
Ln (liver/spleen volume) -0.400 0.028
JOURNAL OF HEPATOLOGYcontrast, whereby the phase shift of flowing blood is proportional
to the velocity. Yzet and colleagues reported that PC-MR was a
more reliable measure of hepatic blood flow compared to Dop-
pler ultrasound with lower variability and higher reproducibility
[18]. In this study, we have shown that within session CoV of theJournal of Hepatology 2016velocity measurement of SMA and SA by PC-MR is less than 10%,
in agreement with a previous study [31].
It is an interesting observation that HVPG can potentially be
assessed non-invasively using a simple linear model of MRI
parameters of liver SE-EPI T1 relaxation time and SA velocity.
Fig. 5 highlights that this linear model provides good prediction
of HVPG across the span of HVPG values from normal to CSPH,
better than SE-EPI liver T1 relaxation time (or SA velocity) alone.
The scan time required to collect the data for this model (Liver T1
and triplicate SA data) is 5–10 min, dependent on breathing rate
of the patient, with PC-MR data being planned whilst the respira-
tory triggered T1 sequence is acquired.
Various non-invasive markers of HVPG, including LSM, have
been reported as being accurate as a binary predictor of the pres-
ence or absence of CSPH [32]. However, we believe that the MR
measures of hepatic architecture and splanchnic haemodynamics
do have the advantage of being able to accurately estimate HVPG
values on a continuous scale as identification of the progression
of portal hypertension beyond the threshold of CSPH (HVPG
P10 mmHg), and this has prognostic implications in patients
with cirrhosis [7,9]. We could potentially utilise this MR model
to monitor the HVPG response in portal hypertensive patients.
For example, MRE has been used for the first time in a recent clin-
ical trial [33], and this proposed algorithm could now be used in
future trials in cirrhosis patients to potentially demonstrate and
assess diagnostic test characteristics, for example to assess
beta-blocker therapy for lowering of HVPG (HVPG to <12 mmHg
or reduction of 20% from baseline).
Here, we have included all patients who were undergoing
HVPG measurements for clinical suspicion of portal hypertensionvol. 65 j 1131–1139 1137
Research Article
in our study population. Although patients without cirrhosis and
portal hypertension were included in the study, this reflects the
use of HVPG and the potential for non-invasive alternatives in
clinical practice. Moreover, the patients included ranged from
those with normal portal pressures to severe portal hypertension
which enabled the MR measures to be evaluated over a wide
range of HVPG values.
In conclusion, in a well characterised patient population, we
have shown that a combination of quantitative MR measures of
liver T1 and SA velocity correlate significantly with HVPG; this
was replicated in our second cohort. If these results are confirmed
by external validation, this non-invasive model including both
architectural (liver T1 relaxation time) and haemodynamic (SA
velocity) measures could be used as a surrogate measure of HVPG
in clinical trials of portal hypertension as well as monitoring
treatment in clinical practice.Financial support
The authors acknowledge the financial support from NIHR Not-
tingham Digestive Diseases Biomedical Research Unit, Notting-
ham University Hospitals NHS Trust and University of
Nottingham, and CORE charity. This paper presents independent
research funded by the National Institute for Health Research
(NIHR). The views expressed are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of
Health.Conflict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conflict of
interest with respect to this manuscript.Authors’ contributions
NP (Acquisition, analysis and interpretation of data, statistical
analysis, drafting of the manuscript); EC (Acquisition, analysis
and interpretation of data, critical revision of the manuscript);
SF (Study concept and design, interpretation of data, drafting
and critical revision of the manuscript); CB, (Acquisition and
analysis of data), RS, RON, GR, ST, HW, RS, PT (Acquisition of
data); AA, ING, GPA (Study concept and design, critical revision
of the manuscript).Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jhep.2016.07.
021.References
[1] Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in
microcirculation and pathophysiology of portal hypertension. Gut
2002;50:571–581.1138 Journal of Hepatology 2016[2] Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient:
Anything worth doing should be done right. Hepatology 2004;39:280–282.
[3] Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R,
et al. Beta-blockers to prevent gastroesophageal varices in patients with
cirrhosis. N Engl J Med 2005;353:2254–2261.
[4] Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al.
Hepatic venous pressure gradient predicts clinical decompensation in
patients with compensated cirrhosis. Gastroenterology 2007;133:481–488.
[5] Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al.
Hepatic venous pressure gradient predicts development of hepatocellular
carcinoma independently of severity of cirrhosis. J Hepatol 2009;50:
923–928.
[6] Garciatsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M.
Portal pressure, presence of gastroesophageal varices and variceal bleeding.
Hepatology 1985;5:419–424.
[7] Merkel C, Bolognesi M, Bellon S, Zuin R, Noventa F, Finucci G, et al. Prognostic
usefulness of hepatic vein catheterization in patients with cirrhosis and
esophageal-varices. Gastroenterology 1992;102:973–979.
[8] Silva-Junior G, Baiges A, Turon F, Torres F, Hernandez-Gea V, Bosch J, et al.
The prognostic value of HVPG in patients with cirrhosis is highly dependent
on the accuracy of the technique. Hepatology 2015;62:1584–1592.
[9] Moitinho E, Escorsell N, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodis J, et al.
Prognostic value of early measurements of portal pressure in acute variceal
bleeding. Gastroenterology 1999;117:626–631.
[10] Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver
stiffness measurement predicts severe portal hypertension in patients with
HCV-related cirrhosis. Hepatology 2007;45:1290–1297.
[11] Garcia-Pagan JC, Gracia-Sancho J, Bosch J. Functional aspects on the
pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012;57:
458–461.
[12] Colecchia A, Montrone L, Scaioli E, Bacchi-Reggiani ML, Colli A, Casazza G,
et al. Measurement of spleen stiffness to evaluate portal hypertension and
the presence of esophageal varices in patients with HCV-related cirrhosis.
Gastroenterology 2012;143:646–654.
[13] Ronot M, Lambert S, Elkrief L, Doblas S, Rautou PE, Castera L, et al.
Assessment of portal hypertension and high-risk oesophageal varices with
liver and spleen three-dimensional multifrequency MR elastography in liver
cirrhosis. Eur Radiol 2014;24:1394–1402.
[14] Iranmanesh P, Vazquez O, Terraz S, Majno P, Spahr L, Poncet A, et al.
Accurate computed tomography-based portal pressure assessment in
patients with hepatocellular carcinoma. J Hepatol 2014;60:969–974.
[15] Baik SK. Haemodynamic evaluation by Doppler ultrasonography in patients
with portal hypertension: a review. Liver Int 2010;30:1403–1413.
[16] Sacerdoti D, Gaiani S, Buonamico P, Merkel C, Zoli M, Bolondi L, et al.
Interobserver and interequipment variability of hepatic, splenic, and renal
arterial Doppler resistance indices in normal subjects and patients with
cirrhosis. J Hepatol 1997;27:986–992.
[17] Hoad CL, Palaniyappan N, Kaye P, Chernova Y, James MW, Costigan C, et al. A
study of T1 relaxation time as a measure of liver fibrosis and the influence of
confounding histological factors. NMR Biomed 2015;28:706–714.
[18] Yzet T, Bouzerar R, Allart JD, Demuynck F, Legallais C, Robert B, et al. Hepatic
vascular flow measurements by phase contrast MRI and doppler echogra-
phy: a comparative and reproducibility study. J Magn Reson Imaging
2010;31:579–588.
[19] Francis ST, Bowtell R, Gowland PA. Modeling and optimization of Look-
Locker spin labeling for measuring perfusion and transit time changes in
activation studies taking into account arterial blood volume. Magn Reson
Med 2008;59:316–325.
[20] McCorry RB, Palaniyappan N, Chivinge A, Kaye P, James MW, Aithal GP.
Development and evaluation of a nurse-led transient elastography service
for the staging of hepatic fibrosis in patients with suspected chronic liver
disease. QJM 2012;105:749–754.
[21] Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al.
Serum markers detect the presence of liver fibrosis: A cohort study.
Gastroenterology 2004;127:1704–1713.
[22] Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R,
et al. Multiparametric magnetic resonance for the non-invasive diagnosis of
liver disease. J Hepatol 2014;60:69–77.
[23] Schmitt P, Griswold MA, Jakob PM, Kotas M, Gulani V, Flentje M, et al.
Inversion recovery TrueFISP: Quantification of T-1, T-2 and spin density.
Magn Reson Med 2004;51:661, 698–698.
[24] Liss P, Cox EF, Eckerbom P, Francis ST. Imaging of intrarenal haemodynamics
and oxygen metabolism. Clin Exp Pharmacol Physiol 2013;40:158–167.
[25] Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G,
et al. Computer-assisted image analysis of liver collagen: relationship tovol. 65 j 1131–1139
JOURNAL OF HEPATOLOGY
ishak scoring and hepatic venous pressure gradient. Hepatology
2009;49:1236–1244.
[26] Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al.
Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
Gastroenterology 2005;128:1898–1906.
[27] Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in
chronic hepatitis C. Hepatology 2003;38:1449–1457.
[28] Mozes FE, Tunnicliffe EM, Pavlides M, Robson MD. Influence of fat on liver T1
measurements using modified Look-Locker inversion recovery (MOLLI)
methods at 3T. J Magn Reson Imaging 2016;44:105–111.
[29] Zwiebel WJ, Mountford RA, Halliwell MJ, Wells PNT. Splanchnic blood-flow
in patients with cirrhosis and portal-hypertension – Investigation with
duplex-doppler us. Radiology 1995;194:807–812.
[30] Sabba C, Weltin GG, Cicchetti DV, Ferraioli G, Taylor KJ, Nakamura T, et al.
Observer variability in echo-Doppler measurements of portal flow in
cirrhotic patients and normal volunteers. Gastroenterology 1990;98:
1603–1611.Journal of Hepatology 2016[31] Cox EF, Smith JK, Chowdhury AH, Lobo DN, Francis ST, Simpson J. Temporal
assessment of pancreatic blood flow and perfusion following secretin
stimulation using noninvasive MRI. J Magn Reson Imaging 2015;42:
1233–1240.
[32] Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, Garcia-Pagan JC, et al.
Elastography, spleen size, and platelet count identify portal hypertension in
patients with compensated cirrhosis. Gastroenterology 2013;144:102–111
e1.
[33] Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, et al. Ezetimibe for
the treatment of nonalcoholic steatohepatitis: assessment by novel mag-
netic resonance imaging and magnetic resonance elastography in a
randomized trial (MOZART trial). Hepatology 2015;61:1239–1250.vol. 65 j 1131–1139 1139
